InSysBio to take part in ESMO Congress 2021

July 28, 2021

July 28, 2021

InSysBio announces its participation in ESMO (European Sosiety For Medical Oncology) Virtual Congress 2021 which is held on September 16-21. InSysBio team’s abstract was accepted:

  • #3143 “Selection of the optimal dose for ALX148, a CD47 blocker, using pharmacokinetic/pharmacodynamic modeling” by Elena Vasileva1,2, Oleg Demin Jr2

Affiliation: 1 Lomonosov Moscow State University, Moscow, Russia; 2InSysBio, Moscow, Russia

Abstract is going to be published on September 13, 2021, 00:05 CEST (Central European Summer Time)

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 120 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit